DYAI news

Latest 2 stories · newest Jun 15, 2026

DYAI

Dyadic highlights accelerated interest in C1 biomanufacturing platform

Dyadic International reports growing interest in its C1 protein production platform for rapid vaccine and antibody manufacturing amid Ebola preparedness efforts. The platform can progress from viral gene sequence to purified antigen in approximately 15 days, positioning the company to address urgent…

Other Jun 15, 2026 sentiment +0.75 SEC filing ↗

DYAI

Dyadic partners with Scripps Research on hantavirus antibody and vaccine development

Dyadic International announced a collaboration with Scripps Research to develop monoclonal antibody and vaccine candidates targeting hantaviruses using its C1 microbial platform. The partnership leverages prior infectious disease research and aims to accelerate biologic production for pandemic prepa…

Other May 28, 2026 sentiment +0.65 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same DYAI feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/DYAI/newsSTART FREE